Author

S. Nance

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. D. Durbin· 2 shared A. E. Goodspeed· 1 shared D. Currier· 1 shared E. P. Danis· 1 shared H. L. Ford· 1 shared H.-M. Lee· 1 shared I. Delahunty· 1 shared J. A. Steele· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. D. Durbin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeutics.

H.-M. Lee, W. C. Wright, M. Pan, J. Low, D. Currier, J. Fang, S. Singh, S. Nance, I. Delahunty, Y. Kim, R. H. Chapple, Y. Zhang, X. Liu, J. A. Steele, J. Qi, , P. Geeleher

The paper uses CRISPR knockout screens to identify drug combinations that enhance the effectiveness of common chemotherapeutics in neuroblastoma cells.

bioRxiv · Apr 12, 2023Cancer Biology

SIX1 Reprograms Myogenic Transcription Factors to Maintain the Rhabdomyosarcoma undifferentiated state

J. Y. Hsu, E. P. Danis, S. Nance, J. O'Brien, V. M. Wessells, A. E. Goodspeed, J. C. Talbot, S. L. Amacher, P. Jedlicka, J. C. Black, J. C. Costello, A. D. Durbin, K. B. Artinger, H. L. Ford

This study shows that SIX1 maintains the undifferentiated state of rhabdomyosarcoma cells by altering MYOD1 activity and enhancer regulation, and a SIX1 loss gene signature predicts RMS progression.

bioRxiv · Apr 25, 2021Cancer Biology